Oral steroid treatment for idiopathic sudden sensorineural hearing loss

Wei T. Chen, MD, Jui W. Lee, MD, Chien H. Yuan, MD, Rong F. Chen, MD

ABSTRACT

Objectives: To describe the efficacy of long-term oral steroids in idiopathic sudden sensorineural hearing loss (ISSHL), and to explore potential prognosis factors, the relationship of hearing recovery outcome, and the recovery time-course in ISSHL.

Methods: In this retrospective study, we analyzed 215 cases diagnosed with idiopathic unilateral sudden deafness between January 2003 and December 2012 at a regional hospital in southern Taiwan. All of them received oral steroid therapy and were followed for at least 3 months.

Results: Young age, the presence of no other disease (diabetes, hypertension, or cardiovascular disease), treatment within 7 days of the onset of ISSHL, mild hearing loss, and audiograms with ascending curves had a statistically significant better hearing recovery. The average pure-tone audiometry (PTA) was 67.8±23.9 dB initially, and was improved between one month (51.6±28.7 dB) and 2 months post treatment (49.7±28.6 dB). The average last-visit PTA was 49.9±29.2 dB.

Conclusion: Approximately one third of patients had full recovery in hearing, one third had partial recovery, and approximately one third did not recover from hearing loss. In addition, the hearing level remained relatively stable following 2 months of treatment. More than 2 months of oral steroid therapy for ISSHL is not recommended because no additional benefits were evidenced.

From the Department of Otolaryngology, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan, Republic of China.

Disclosure. Authors have no conflict of interests, and the work was not supported or funded by any drug company.
idiopathic sudden sensorineural hearing loss (ISSHL) is defined as a sensorineural hypoacusis of at least 30 dB over 3 consecutive speech frequencies, occurring within 3 days. It is considered to be an otologic emergency, and the incidence has been estimated to range from 3.9 to 27.5 per 100,000 persons per year. Although the exact cause is still unknown, it has been hypothesized to be caused by viral infection of the labyrinth or cochlear nerve, vascular insult, intra labyrinthine membrane rupture, and autoimmunity. Owing to the variations in the etiopathogenesis of ISSHL, different therapeutic strategies have been developed. Steroids or in combination with vasodilators, plasma expanders, diuretics, anticoagulants, antiviral, vitamins, cytotoxic medications, hyperbaric oxygen, stellate ganglion block, and inhaled carbogen, have become the most widely accepted treatment options. However, the length of oral steroid therapy had not been well established. Most of the studies reported the length of steroid therapy ranging between 5-24 days. Although little is known about the time course of hearing loss for most patients, improvement in hearing can be anticipated only during the first 1-2 months. Therefore, this study investigated progression in recovery from sudden hearing loss, and the optimal treatment duration with oral steroids.

**Methods.** A retrospective chart review was performed in the Department of Otolaryngology, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan between January 2003 and December 2012. The study followed the principals of the Helsinki Declaration.

**Study participants.** All patients with unilateral ISSHL were identified. Exclusion criteria was defined as: 1) Patients who were treated with ISSHL previously, and 2) patients with perilymphatic fistulas, acoustic trauma, acoustic tumors, Meniere’s disease, severe infection, pregnancy, peptic ulcer disease, and allergy to steroids. The data were collected from a total of 215 affected ears.

**Treatment procedure.** Once ISSHL was diagnosed, patients were hospitalized for one week, followed by outpatient clinic visits for at least 3 months. The standard medical treatment in hospitalization consisted of oral administration of high-dose steroids, oral pentoxifylline (400 mg twice per day), and intravenous administration of low-molecular-weight dextran. The prednisolone dose was one mg/kg body weight per day for 4 days, followed by a 3-day taper during admission (0.8 mg/kg, 0.6 mg/kg, and to 0.4 mg/kg). Thereafter, all patients were prescribed with a tapering dosing of oral steroids for 3 months according to the hearing improvement.

**Evaluation.** The determination of hearing change was based on the 4-tone average (arithmetic mean) of thresholds at 0.5, 1, 2, and 4 kHz. Hearing recovery was measured with Siegel’s criteria and according to the classification: type I (complete recovery) included patients whose final hearing level was better than 25 dB regardless of the size of the gain; type II (partial recovery) included patients who showed more than 15 dB of gain and whose final hearing level was between 25 and 45 dB; type III (slight recovery) included patients who showed more than 15 dB of gain and whose final hearing level was poorer than 45 dB; and type IV (no improvement) included patients who showed less than 15 dB of gain. Pure-tone audiometry (PTA) was performed on the initial day and the first, second, and third month (revising data) after treatment and at the last clinic visit (last visit PTA).

The variables that potentially affected recovery from ISSHL, including patient gender, age, the affected side of ear, the patient's medical history (diabetes mellitus, hypertension, or cardiovascular disease), presence or absence of vertigo or tinnitus, beginning of treatment, severity of hearing loss, and the audiogram shape, were analyzed. The initial (pretreatment) audiogram was classified with the severity of hearing loss as mild (under 45 dB), moderate (46 to 90 dB), and severe ISSHL (over 90 dB). The initial audiogram was labeled as upsloping (left to right), downsloping (left to right), flat, and total deaf pattern according to Sheehy's classification.

**Statistical analysis.** Statistical analysis was performed with the Statistical Package for Social Sciences (SPSS Inc., Chicago, IL, USA) program Version 17.0. Analysis of each prognostic factor, included gender, affected ear, diabetes, hypertension, cardiovascular disease, tinnitus, vertigo, time to treatment, and the pre- and post-treatment of the average PTA was performed with unpaired t-test. One-way analysis of variance (ANOVA) was used to study the relationship between age group, or the severity of hearing loss, and hearing recovery. The post hoc test was analyzed for pairwise comparison for type of initial audiogram. All data in this study was presented as mean ± standard deviation. A p-value less than 0.05 was considered significant.

**Results.** Of the 215 cases in the current study, 112 (52.1%) were men and 103 (47.9%) were women. The mean age of this group was 48.7 years (range from 9 to 91). On hundred and three (47.9%) of the affected ears were on the right side and 112 (52.1%) on the left. Analysis of medical history showed that 15.8% had type 2 diabetes mellitus, 9.3% had hypertension, and 3.7% had cardiovascular diseases. Tinnitus was present...
at the time of insult for more than half (54.4%) of the patients. The ISSHL was accompanied by vertigo in around 6% of the patients in this study. The interval between the onset of symptoms and treatment ranged from 0 to 14 days, with a mean of 4.7 ± 3.7 days.

Table 1 shows that diabetes ($p=0.002$), hypertension ($p=0.002$), cardiovascular disease ($p=0.002$), and treatment beginning later than 7 days after onset of ISSHL ($p=0.03$) were statistically significantly associated with a poorer recovery from hearing loss. However, gender ($p=0.46$), affected ear ($p=0.36$), presence of tinnitus ($p=0.15$), and vertigo ($p=0.06$) did not significantly influence recovery from hearing loss.

Table 2 indicates that younger age ($p<0.001$) and mild hearing loss ($p<0.001$) had a statistically significant better hearing recovery. Table 3 demonstrates that significantly better hearing recovery was seen in patients with ascending curve audiograms than in those with descending curve, flat audiograms, and total hearing loss (all $p<0.05$).

The study group was classified according to Siegel’s classification as follows: 33% with type I, 18.1% with type II, 14% with type III, and 34.9% with type IV. The relationship between Siegel’s classification and the time lapse from treatment to the final recovery is shown in Table 4. Among the 76 patients whose hearing started to recover after discharge, 81.6% (62 patients) acquired the final hearing level within one month after treatment, 9.2% (7 patients) between 1-2 months, 3.9% (3 patients) between 2-3 months, and 5.3% (4 patients) obtained the final hearing level at more than 3

### Table 1 - Follow-up results of idiopathic sudden sensorineural hearing loss patients related to demographic, and clinical characteristics in 215 patients.

| Prognostic factor | Cases (n) | Complete recovery (I) (%) | Partial recovery (II) (%) | Slight recovery (III) (%) | No recovery (IV) (%) |
|-------------------|-----------|---------------------------|---------------------------|--------------------------|---------------------|
| **Gender**        |           |                           |                           |                          |                     |
| Male              | 112       | 37 (33.0)                 | 20 (17.9)                 | 15 (13.4)                | 40 (35.7)           |
| Female            | 103       | 34 (33.0)                 | 19 (18.4)                 | 15 (14.6)                | 35 (34.0)           |
| **Affected ear**  |           |                           |                           |                          |                     |
| Right             | 103       | 32 (31.1)                 | 16 (15.5)                 | 18 (17.5)                | 37 (35.9)           |
| Left              | 112       | 39 (34.8)                 | 23 (20.6)                 | 12 (10.7)                | 38 (33.9)           |
| **Diabetes mellitus** |       |                           |                           |                          |                     |
| Positive          | 34        | 5 (14.7)                  | 7 (20.6)                  | 6 (17.6)                 | 16 (47.1)           |
| Negative          | 181       | 66 (36.4)                 | 32 (17.7)                 | 24 (13.3)                | 59 (32.6)           |
| **Hypertension**  |           |                           |                           |                          |                     |
| Positive          | 20        | 2 (10.0)                  | 3 (15.0)                  | 3 (15.0)                 | 12 (60.0)           |
| Negative          | 195       | 69 (35.4)                 | 36 (18.5)                 | 27 (13.8)                | 63 (32.3)           |
| **Cardiovascular diseases** | |                           |                           |                          |                     |
| Positive          | 8         | 0 (0)                     | 1 (12.5)                  | 1 (12.5)                 | 6 (75.0)            |
| Negative          | 207       | 71 (34.3)                 | 38 (18.4)                 | 29 (14.0)                | 69 (33.3)           |
| **Tinnitus**      |           |                           |                           |                          |                     |
| Positive          | 117       | 41 (35.1)                 | 20 (17.1)                 | 19 (16.2)                | 37 (31.6)           |
| Negative          | 98        | 30 (30.6)                 | 19 (19.4)                 | 11 (11.2)                | 38 (38.8)           |
| **Vertigo**       |           |                           |                           |                          |                     |
| Positive          | 13        | 3 (23.1)                  | 1 (7.7)                   | 4 (30.7)                 | 5 (38.5)            |
| Negative          | 202       | 68 (33.7)                 | 38 (18.8)                 | 26 (12.9)                | 70 (34.6)           |
| **Time to treatment** |      |                           |                           |                          |                     |
| ≤7 days           | 190       | 68 (35.8)                 | 35 (18.4)                 | 29 (15.3)                | 58 (30.5)           |
| >7 days           | 25        | 3 (12.0)                  | 4 (16.0)                  | 1 (4.0)                  | 17 (68.0)           |
months after treatment. The mean time interval between initial and last visit was 14 ± 22.3 months (range from 6 months to 8 years 5 months). The average PTA was 67.8 ± 23.9 dB initially, and was improved to 54.9 ± 27.3 dB at discharge.

Our data showed that there was a statistically significant difference in the average PTA measured between one month (51.6 ± 28.7 dB) and 2 months post treatment (49.7 ± 28.6 dB) (p=0.02). However, the average PTAs measured between 2 and 3 months post treatment were not statistically different between each other (p=0.34). The average last-visit PTA was 49.9 ± 29.2 dB. The data revealed that hearing was not improved further after 2 months of treatment for ISSHL patients.

In our study, the complications of a long-term course of oral steroid administration showed the 12.1% of 215 patients were hyperglycemic, 5.1% had high blood pressure, 0.5% had gastrointestinal bleeding, 1.9% had psychiatric disorders (agitation, anxiety, fear, insomnia, irritability, lethargy, and mood lability), and 25.1% had other adverse events (weight gain, or cutaneous adverse events). In addition, osteoporosis was not found in this trial.

Discussion. Idiopathic sudden sensorineural hearing loss was first reported by Kleyn DA in 1944.
Idiopathic sudden sensorineural hearing loss ... Chen et al

and called sudden deafness by Hallberg in 1956. The etiology has not been elucidated; however, pathophysiological studies have suggested that ISSHL is caused by hypo-oxygenation and resultant metabolic block due to localized ischemia at the inner ear. The natural history of ISSHL varies owing to the multiple factors involved in the pathogenesis. Our data showed hypertension, cardiovascular disease, and diabetes mellitus were prognostic factors for poor recovery from ISSHL. Therefore, these diseases were proposed to be related to the pathogenesis of ISSHL.

Many previous studies reported that the initial symptoms at the onset of ISSHL may serve as a predictor of the prognosis that tinnitus is considered to be a positive prognostic indicator, but the presence of vertigo has been shown to be a negative prognostic factor. In the current study, no significant difference in recovery was found between patients with and without tinnitus. This may be because tinnitus potentially was a sequelae of hearing impairment, similar to that in patients with presbycusis. Furthermore, patients with vertigo had poorer hearing recovery compared with patients without vertigo in our study. However, the data showed no statistical significance.

We sought to identify other variables that may help predict clinical improvement. Our results revealed that younger age, mild hearing loss, and an ascending curve audiogram on presentation correlated with improved outcomes. We also noted that the “golden hour” for ISSHL is 7 days. Of course, better recovery from hearing loss was shown in patients who were treated early. These findings are also consistent with previous reports on ISSHL.

Understanding the progression of ISSHL is important in planning the treatment, estimating the necessary follow-up course, and evaluating the potential outcome. Owing to the variations in the etiopathogenesis of ISSHL, different therapeutic strategies have been developed. However, the length of oral steroid therapy has not been well established, and the prior studies were unclear. In our study, all patients received long-term for 3 months. Our data revealed that hearing was not improved further after two months of treatment for ISSHL patients. As 2 months of treatment is adequate, it may not be beneficial for patients to take excessive dose of steroids for long-term recovery. Some studies also showed that no change of hearing level is expected after 2 months of treatment of ISSHL. It is possible that the period of 2 months is embedded in the natural history of the disease, regardless of the treatment protocols. Therefore, any treatment after 2 months may not affect the outcome.

Our clinical observation showed that there may still be enough time for alternative treatments even if the patients did not respond to the initial high-dose steroid regime. All patients in the current study were prescribed with oral steroids only, and none received additional therapy, such as intratympanic steroid administration, intratympanic dexamethasone with hyaluronic acid, hyperbaric oxygen, carbogen inhalation, or others. It was shown that 6.5% of 215 patients had delayed recovery occurring later than one month after treatment, whereas 3.3% recovered 2 months after treatment, and hearing was further improved over a period of 3 months. However, the percentage was lower than those reported in other studies where intratympanic steroid administration was used as a salvage treatment to achieve better hearing recovery. It is notable that the alternative therapy was performed within 2 months after initial therapy for ISSHL. It is recommended, therefore, that the additional therapy should be performed in patients who do not respond to the initial therapy with expected progress within 2 months. In addition, in other studies, intratympanic dexamethasone with hyaluronic acid was used as the additional therapy, and the combination of dexamethasone with a modified hyaluronic acid hydrogel yields significantly higher sustainable perilymph dexamethasone concentrations than by using dexamethasone alone.17

The limitation of this study was the limited number of patients and our patients were followed for the average value of 14 months, but they may be followed for more than 5 or 10 years in the future.

Further research is needed to support a causal relationship and its clinical implications. In addition, there are more factors to consider such as laboratory data, and the sample size with long-term follow up may be increased.

In conclusion, based on a retrospective analysis of ISSHL patients, we found that approximately one third of patients had full recovery in hearing, one third had partial recovery, and around one third did not recover from hearing loss. We demonstrate that the hearing remained relatively stable after 2 months of treatment for ISSHL, and emphasize a steroid regime for ISSHL lasting longer than 2 months is not recommended since additional benefits were not evidenced.

References

1. Nosrati-Zarenoe R, Hansson M, Hultcrantz E. Assessment of diagnostic approaches to idiopathic sudden sensorineural hearing loss and their influence on treatment and outcome. Acta Otolaryngol 2010; 130: 384-391.
2. Mamak A, Yilmaz S, Cansiz H, Inci E, Güçlü E, DEREKÖYLU L. A study of prognostic factors in sudden hearing loss. *Ear Nose Throat J* 2005; 84: 641-644.
3. Siegel LG. The treatment of idiopathic sudden sensorineural hearing loss. *Otolaryngol Clin North Am* 1975; 8: 467-473.
4. Panda NK, Verma RK, Saravanan K. Sudden sensorineural hearing loss: have we got a cure? *J Otolaryngol Head Neck Surg* 2008; 37: 807-812.
5. Lee HJ, Park CY, Lee JH, Yang HS, Kim JH, Ban MJ, et al. Therapeutic effects of carbogen inhalation and lipo-prostaglandin E1 in sudden hearing loss. *Yonsei Med J* 2012; 53: 999-1004.
6. Suzuki H, Tabata T, Koizumi H, Hohchi N, Takeuchi S, Kitamura T, et al. Prediction of hearing outcomes by multiple regression analysis in patients with idiopathic sudden sensorineural hearing loss. *Ann Otol Rhinol Laryngol* 2014; 123: 821-825.
7. Lee HS, Lee YJ, Kang BS, Lee BD, Lee JS. A clinical analysis of sudden sensorineural hearing loss cases. *Korean J Audiol* 2014; 18: 69-75.
8. Sheehy JL. Vasodilator therapy in sensory-neural hearing loss. *Laryngoscope* 1980; 70: 885-914.
9. Kleyn DA. Sudden complete or partial loss of function of the octarous-system in apparently normal person. *Acta Otolaryngol* 1944; 32: 407-429.
10. Hallberg OE. Sudden deafness of obscure origin. *Laryngoscope* 1956; 66: 1237-1267.
11. Schulz S, Ritter J, Oertel K, Witt K, Bär KJ, Guntinas-Lichius O, et al. Altered autonomic regulation as a cardiovascular risk marker for patients with sudden sensorineural hearing loss. *Otol Neurotol* 2014; 35: 1720-1729.
12. Ryu OH, Choi MG, Park CH, Kim DK, Lee JS, Lee JH. Hyperglycemia as a potential prognostic factor of idiopathic sudden sensorineural hearing loss. *Otolaryngol Head Neck Surg* 2014; 150: 853-858.
13. Cvorović L, Deric D, Probst R, Hegemann S. Prognostic model for predicting hearing recovery in idiopathic sudden sensorineural hearing loss. *Otol Neurotol* 2008; 29: 464-469.
14. Zhao H, Zhang TY, Jing JH, Fu YY, Luo JN. [Prognostic factors for patients with the idiopathic sudden sensorineural hearing loss]. *Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi* 2008; 43: 660-664. Chinese
15. Kanzaki J, Taji H, Ogawa K. Evaluation of hearing recovery and efficacy of steroid treatment in sudden deafness. *Acta Otolaryngol Suppl* 1988; 456: 31-36.
16. Psifidis AD, Psillas GK, Danilidis JCh. Sudden sensorineural hearing loss: long-term follow-up results. *Otolaryngol Head Neck Surg* 2006; 134: 809-815.
17. Kawano T, Matsuura M, Ishitoya J, Oritate N. [Efficacy of intratympanic steroid treatment for idiopathic sudden sensorineural hearing loss after failure of intravenous steroid treatment]. *Nihon Jibiinkoka Gakkai Kaiho* 2014; 117: 802-808. Japanese
18. Dispenza F, De Stefano A, Costantino C, Marchese D, Riggio F. Sudden sensorineural hearing loss: results of intratympanic steroids as salvage treatment. *Am J Otolaryngol* 2013; 34: 296-300.
19. Wu HP, Chou YF, Yu SH, Wang CP, Hsu CJ, Chen PR. Intratympanic steroid injections as a salvage treatment for sudden sensorineural hearing loss: a randomized, double-blind, placebo-controlled study. *Otol Neurotol* 2011; 32: 774-779.
20. Arastou S, Tajedini A, Borgheri P. Combined intratympanic and systemic steroid therapy for poor-prognosis sudden sensorineural hearing loss. *Iran J Otorhinolaryngol* 2013; 25: 23-28.
21. Gouveris H, Schuler-Schmidt W, Mewes T, Mann W. Intratympanic dexamethasone/hyaluronic acid mix as an adjunct to intravenous steroid and vasoactive treatment in patients with severe idiopathic sudden sensorineural hearing loss. *Otol Neurotol* 2011; 32: 756-760.
22. Borden RC, Saunders JE, Berryhill WE, Krempel GA, Thompson DM, Queimado L. Hyaluronic acid hydrogel sustains the delivery of dexamethasone across the round window membrane. *Audiol Neurootol* 2011; 16: 1-11.

### Related Articles

Al-Ani RM, Mohsin TM, Hassan ZM, Al-Dulaimy HI. Importance of ophthalmological examination in children with congenital sensorineural hearing loss. *Saudi Med J* 2009; 30: 1197-1201.

Al-Dousary SH. Mobile phone induced sensorineural hearing loss. *Saudi Med J* 2007; 28: 1283-1286.

Lasisi AO, Salako BL, Kodiya MA, Amusat MA, Osisanya WP. Hearing threshold in patients with chronic renal failure. *Saudi Med J* 2007; 28: 744-746.